Effect Of Iguratimod Combined With Methotrexate On Serum VEGF Level In Patients With Rheumatoid Arthritis And Evaluation Of Efficacy

Objective: to study the Iguratimod combined with Methotrexate for rheumatoid arthritis(RA)patients with serum vascular endothelial growth factor(VEGF),observe its curative effect for the treatment of RA.Methods: 60 patients with active RA with definite diagnosis were randomly divided into experimental group and control group.The experimental group was treated with Iguratimod combined with Mthotrexate orally,while the control group was treated with Leflunomide combined with Methotrexate orally.The observation period was 12 weeks.Serum VEGF levels of RA patients were measured before and 12 weeks after treatment,and DAS28 score was calculated according to clinical symptoms and laboratory indexes of RA patients before and 12 weeks after treatment to evaluate the treatment effect.Results: Thent was(4.43±0.68).The difference was not statistically significant(P>0.05).After 1ere was no statistically significant difference in the general data between the two groups.The serum VEGF level(89.48±50.13)pg/ml before treatment in the experimental group and the serum VEGF level(81.56±44.26)pg/ml before treatment in the control group were not statistically significant(P>0.05).After 12 weeks of treatment,serum VEGF level(20.56±18.11)pg/ml in the experimental group,serum VEGF level(38.82±36.75)pg/ml in the control group after 12 weeks of treatment,significantly decreased compared with before treatment,and the difference was statistically significant.Significance(experimental group:t=6.923,P<0.01,control group: t=6.021,P<0.01);serum VEGF levels in the experimental group were significantly lower,the difference was statistically significant(t=2.141,P<0.05).The DAS28 score of the experimental group was(4.53±0.71)before treatment,and the DAS28 score of the control group before treatm2 weeks of treatment,the DAS28 score of the experimental group was(3.07±0.93).After 12 weeks of treatment,the DAS28 score of the control group was(3.62±0.62),which was decreased compared with that before treatment,and the difference was statistically significant(experimental group: t =12.681,P<0.01,control group: t=9.679,P<0.01);the DAS28 score in the experimental group was significantly lower,the difference was statistically significant(t=4.501,P<0.01).Conclusion: Iguratimod combined with Methotrexate can significantly reduce serum VEGF levels and DAS28 scores in patients with RA,and exert anti-angiogenic,anti-inflammatory,and bone protection effects,with a positive effect and few adverse reactions.Iguratimod combined with Methotrexate in the aspects of the effect is better than to Leflunomide combined with Methotrexate.